Agilon health/$AGL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Agilon health
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
Ticker
$AGL
Sector
Primary listing
NYSE
Employees
1,076
Headquarters
Website
Agilon health Metrics
BasicAdvanced
$392M
-
-$0.77
0.14
-
Price and volume
Market cap
$392M
Beta
0.14
52-week high
$6.08
52-week low
$0.71
Average daily volume
6.8M
Financial strength
Current ratio
1.163
Quick ratio
1.123
Long term debt to equity
1.572
Total debt to equity
10.117
Interest coverage (TTM)
-59.56%
Profitability
EBITDA (TTM)
-347.304
Gross margin (TTM)
-1.76%
Net profit margin (TTM)
-5.35%
Operating margin (TTM)
-6.34%
Effective tax rate (TTM)
-0.43%
Revenue per employee (TTM)
$5,480,000
Management effectiveness
Return on assets (TTM)
-12.07%
Return on equity (TTM)
-60.68%
Valuation
Price to revenue (TTM)
0.066
Price to book
0.96
Price to tangible book (TTM)
1.23
Price to free cash flow (TTM)
-4.245
Free cash flow yield (TTM)
-23.56%
Free cash flow per share (TTM)
-0.223
Growth
Revenue change (TTM)
11.76%
Earnings per share change (TTM)
3.36%
3-year revenue growth (CAGR)
38.01%
3-year earnings per share growth (CAGR)
39.71%
What the Analysts think about Agilon health
Analyst ratings (Buy, Hold, Sell) for Agilon health stock.
Bulls say / Bears say
In Q4 2024, agilon’s revenue rose 44% year-over-year to $1.52 billion and Medicare Advantage membership climbed 36% to 527,000, reflecting strong demand for its value-based care platform (Business Wire).
For Q1 2025, agilon posted net income of $12 million and adjusted EBITDA of $21 million, turning a profit compared with a $6 million net loss and $29 million EBITDA loss in Q1 2024. The company reaffirmed its full-year guidance, signaling better operational leverage (Business Wire).
In May 2025, agilon formed five new physician partnerships, expanding its network to over 3,000 primary care physicians serving more than 700,000 seniors in 30-plus markets and entering Illinois. This growth strengthens its scale and value-based care reach (Business Wire )(Business Wire).
Agilon’s Q2 2025 results missed expectations, with revenue declining 6% year-over-year to $1.395 billion, a net loss of $104 million, and an adjusted EBITDA loss of $83 million. The company suspended its full-year outlook and shares dropped more than 25% in pre-market trading (Investing.com).
In Q2 2025, agilon reported a negative gross profit of $52 million and a medical margin loss of $53 million, reversing from a $32 million gross profit and a $106 million medical margin in Q2 2024. This highlights ongoing underwriting and risk adjustment issues (Business Wire).
CEO Steven Sell resigned on August 4, 2025 after disappointing Q2 results, leading to the formation of an interim 'Office of the Chairman' and the withdrawal of FY 2025 guidance, raising concerns about leadership stability and strategy (Business Wire).
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Agilon health Financial Performance
Revenues and expenses
Agilon health Earnings Performance
Company profitability
Agilon health News
AllArticlesVideos
Rosen Law Firm Encourages agilon health, inc. Investors to Inquire About Securities Class Action Investigation – AGL
Business Wire4 days ago
agilon health Sets Date to Report Third Quarter 2025 Financial Results
Business Wire7 days ago
AGILON HEALTH INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of agilon health, inc. - AGL
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Agilon health stock?
Agilon health (AGL) has a market cap of $392M as of October 13, 2025.
What is the P/E ratio for Agilon health stock?
The price to earnings (P/E) ratio for Agilon health (AGL) stock is 0 as of October 13, 2025.
Does Agilon health stock pay dividends?
No, Agilon health (AGL) stock does not pay dividends to its shareholders as of October 13, 2025.
When is the next Agilon health dividend payment date?
Agilon health (AGL) stock does not pay dividends to its shareholders.
What is the beta indicator for Agilon health?
Agilon health (AGL) has a beta rating of 0.14. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.